3.98
-0.17 (-4.10%)
| Penutupan Terdahulu | 4.15 |
| Buka | 4.29 |
| Jumlah Dagangan | 252,616 |
| Purata Dagangan (3B) | 140,433 |
| Modal Pasaran | 91,125,680 |
| Harga / Jualan (P/S) | 52.50 |
| Harga / Buku (P/B) | 1.46 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.78 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.03% |
| Nisbah Semasa (MRQ) | 20.34 |
| Aliran Tunai Operasi (OCF TTM) | -50.76 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -33.03 M |
| Pulangan Atas Aset (ROA TTM) | -24.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Sagimet Biosciences Inc. - Seri | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.03% |
| % Dimiliki oleh Institusi | 44.74% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 35.00 (Citizens, 779.40%) | Beli |
| Median | 28.00 (603.52%) | |
| Rendah | 8.00 (Barclays, 101.01%) | Pegang |
| Purata | 24.75 (521.86%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 6.52 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 03 Feb 2026 | 27.00 (578.39%) | Beli | 6.23 |
| HC Wainwright & Co. | 03 Feb 2026 | 29.00 (628.64%) | Beli | 6.23 |
| Barclays | 28 Jan 2026 | 8.00 (101.01%) | Pegang | 5.86 |
| Citizens | 14 Nov 2025 | 35.00 (779.40%) | Beli | 7.75 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |